Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 11, 2010, Pages 1633-1640

  Li, Chuanxing ^a   Zhang, Fujun ^a   Zhang, Weidong ^a   Zhang, Liang ^a   Huang, Zilin ^a   Wu, Peihong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

125I brachytherapy; Hepatocellular carcinoma; Liver transplantation; Lung metastases; Sorafenib

Indexed keywords

IODINE 125; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PYRIDINE DERIVATIVE; RADIOACTIVE IODINE;

ADULT; ARTICLE; BLEEDING; BRACHYTHERAPY; CANCER CONTROL; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIARRHEA; FATIGUE; FEASIBILITY STUDY; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LUNG METASTASIS; MALE; OVERALL SURVIVAL; PATIENT SAFETY; PNEUMOTHORAX; PRIORITY JOURNAL; RADIATION DOSE; SKIN MANIFESTATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM METASTASIS; PATHOLOGY; PATIENT CARE PLANNING; PROCEDURES; SECONDARY; TIME;

ADULT; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PATIENT CARE PLANNING; PYRIDINES; SURVIVAL RATE; TIME FACTORS; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 77957579602     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0821-z     Document Type: Article

References (35)

1. JC Blasko TM John S Peter, et al. 2002 Brachytherapy for carcinoma of the prostate: techniques, patients selection and clinical outcome Semi Radiat Oncol 12 81 84 10.1053/srao.2002.28667
2. DF Calvisi S Ladu A Gorden, et al. 2006 Ubiquitous activation of Ras and Jak/Stat pathways in human HCC Gastroenterology 130 1117 1128 1:CAS:528:DC%2BD28XksFWmurg%3D 10.1053/j.gastro.2006.01.006 16618406
3. YS Chang J Adnane PA Trail, et al. 2007 Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models Cancer Chemother Pharmacol 59 561 574 1:CAS:528: DC%2BD2sXhvVeiuro%3D 10.1007/s00280-006-0393-4 17160391 (Pubitemid 46295136)
4. Z Chen F He F Zeng, et al. 2006 Impact of steroid withdrawal on recurrent rate of carcinoma after liver transplantation of hepatocellular carcinoma Chin J Organ Transpl 27 156 159 1:CAS:528:DC%2BD2sXhtFGltbnP
5. S Deuffic T Poynard L Buffat, et al. 1998 Trends in primary liver cancer Lancet 351 214 215 1:STN:280:DyaK1c7htFGntA%3D%3D 10.1016/S0140-6736(05)78179-4 9449893
6. HB El-Serag AC Mason 1999 Rising incidence of hepatocellular carcinoma in the United States N Engl J Med 340 745 750 1:STN:280:DyaK1M7ls1ensg%3D%3D 10.1056/NEJM199903113401001 10072408 (Pubitemid 29114292)
7. Y Ito Y Sasaki M Horimoto, et al. 1998 Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma Hepatology 27 951 958 1:CAS:528:DyaK1cXisFCksbg%3D 10.1002/hep.510270409 9537433 (Pubitemid 28160479)
8. GB Klintmalm 2004 The history of organ transplantation in the Baylor Health Care System Proc (Bayl Univ Med Cent) 17 23 34
9. HH Lee JW Joh JH Park, et al. 2005 Microvascular tumor embolism: independent prognostic factor after liver transplantation in hepatocellular carcinoma Transplant Proc 37 1251 1253 1:STN:280:DC%2BD2M3hsFShug%3D%3D 10.1016/j.transproceed.2005.01.018 15848686 (Pubitemid 40590853)
10. TA Leslie JE Kennedy RO Illing, et al. 2008 High-intensity focused ultrasound ablation of liver tumours: can radiological assessment predict the histological response Br J Radiol 81 564 571 1:STN:280:DC%2BD1czpt12muw%3D%3D 10.1259/bjr/27118953 18559903 (Pubitemid 351957742)
11. 125I source Med Phys 27 1275 1280 1:STN:280:DC%2BD3M%2Fit1antg%3D%3D 10.1118/1.599005 10902556 (Pubitemid 30416095)
12. CC Ling 1992 Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model Int J Radiat Oncol Biol Phys 23 81 87 1:STN:280:DyaK383kt1Wkug%3D%3D 1572833
13. SA Little Y Fong 2001 Hepatocellular carcinoma: current surgical management Semin Oncol 28 474 486 1:STN:280:DC%2BD3MngvVOhug%3D%3D 10.1016/S0093-7754(01)90140-X 11685740
14. L Liu Y Cao C Chen, et al. 2006 Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 11851 11858 1:CAS:528:DC%2BD28Xhtlagu73F 10.1158/0008-5472.CAN-06-1377 17178882 (Pubitemid 46094197)
15. JM Llovet S Ricci V Mazzaferro, et al. 2007 Sorafenib improves survival in advanced hepatocellular carcinoma: results of a phase III randomized placebocontrolled trial J Clin Oncol 25 LBA1
16. JM Llovet S Ricci V Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 1:CAS:528:DC%2BD1cXovFWjsL8%3D 10.1056/NEJMoa0708857 18650514
17. U Markus S Ulrich K Gabriele, et al. 2006 Evaluation of tumour necrosis during chemotherapy with diffusion-weighted MR imaging: preliminary results in osteosarcomas Pediatr Radiol 36 1306 1311 10.1007/s00247-006-0324-x (Pubitemid 44920869)
18. JJ Mazeron G Noel JM Simon 2002 Head and neck brachytherapy Semi Raidat Oncol 12 95 108 10.1053/srao.2002.28668
19. V Mazzaferro E Regalia R Doci, et al. 1996 Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 693 699 1:STN:280:DyaK287nsFWltw%3D%3D 10.1056/NEJM199603143341104 8594428 (Pubitemid 26079803)
20. V Mazzaferro E Regalia R Doci, et al. 1996 Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 693 699 1:STN:280:DyaK287nsFWltw%3D%3D 10.1056/NEJM199603143341104 8594428 (Pubitemid 26079803)
21. B Perez Saborido C Loinaz Segurola A Gimeno Calvo, et al. 2003 Liver transplantation for hepatocellular carcinoma: our experience from 1986 Transplant Proc 35 1825 1826 1:STN:280:DC%2BD3svitlCksg%3D%3D 10.1016/S0041-1345(03)00581-5 12962810 (Pubitemid 37093726)
22. H Pokorny M Gnant S Rasoul-Rockenschaub, et al. 2005 Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant 5 788 794 1:CAS:528:DC%2BD2MXjtlaitrc%3D 10.1111/j.1600-6143.2005.00780.x 15760403 (Pubitemid 40461289)
23. RT Poon ST Fan CM Lo, et al. 2002 Long term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation Ann Surg 235 373 382 10.1097/00000658-200203000-00009 11882759 (Pubitemid 34183888)
24. M Ravaioli GL Grazi G Ercolani, et al. 2004 Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation Transplantation 78 1780 1786 10.1097/01.TP.0000145892.97114.EE 15614151 (Pubitemid 40041645)
25. HJ Schlitt M Neipp A Weimann, et al. 1999 Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation J Clin Onco 17 324 1:STN:280:DyaK1MzosFCgsA%3D%3D
26. D Semela JF Dufour 2004 Angiogenesis and hepatocellular carcinoma J Hepatol 41 864 880 10.1016/j.jhep.2004.09.006 15519663 (Pubitemid 39434320)
27. ZX Shao X Xu SS Zheng, et al. 2006 Serum α-fetoprotein alterations and tumor recurrence after liver transplantation for hepatocellular carcinoma patients Chin J of Gen Surg 21 351 353
28. P Sharma V Balan JL Hernandez, et al. 2004 Liver transplantation for hepatocellular carcinoma: the MELD impact Liver Transpl 10 36 41 10.1002/lt.20012 14755775 (Pubitemid 38885890)
29. SD Taylor-Robinson GR Foster S Arora, et al. 1997 Increase in primary liver cancer in the UK Lancet 350 1142 1143 1:STN:280:DyaK1c%2FgtlWjtA%3D%3D 10.1016/S0140-6736(05)63789-0 9343506
30. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
31. A Villanueva P Newell DY Chiang, et al. 2007 Genomics and signaling pathways in hepatocellular carcinoma Semin Liver Dis 27 55 76 1:CAS:528:DC%2BD2sXjtlWrsLs%3D 10.1055/s-2006-960171 17295177
32. M Vivarelli R Bellusci A Cucchetti, et al. 2002 Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 74 1746 1751 10.1097/00007890- 200212270-00017 12499891 (Pubitemid 36019329)
33. SM Wilhelm C Carter L Tang, et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099 7109 1:CAS:528:DC%2BD2cXotFalsbk%3D 10.1158/0008-5472.CAN-04-1443 15466206 (Pubitemid 39331023)
34. FY Yao L Ferrell NM Bass, et al. 2001 Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival Hepatology 33 1394 1403 1:STN:280:DC%2BD3MzhvFajtQ%3D%3D 10.1053/jhep.2001.24563 11391528 (Pubitemid 32496976)
35. SS Zheng X Xu TB Liang, et al. 2005 Liver transplantation for hepatocellular carcinoma: prognostic analysis of 89 case Chin J Surg 43 450 453 15854372